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A b s t r a c t  
Acyclovir is an antiviral drug, belonging to the deoxyguanosine family, widely prescribed for the 
treatment of herpes simplex viral infections, as well as in the treatment of herpes zoster (shingles). 
Oral bioavailability of acyclovir is very low (10–20%) owing to its first pass metabolism with 
elimination half-life (t1/2) of 2-3 h. It has absorption window in upper gastrointestinal tract. Due to its 
rapid elimination from site of absorption and short biological half life, sustained release formulation 
system for acyclovir is advantageous. In this study, gastro retentive mucoadhesive SR pellets of 
acyclovir was prepared using HPMC K 100M as matrix former and Sodium CMC as mucoadhesive 
polymer by extrusion spheronization technique. Acyclovir pellets prepared with higher concentration 
of HPMC (batch G) showed in vitro drug release for 12 h with sufficient mucoadhesion strength and 
ex vivo resident time. Release kinetic studies indicated that drug release data had best fit to 
Higuchi’s model. In-vivo studies in rat model proved that relative bioavailability of acyclovir SR 
pellets get increased by 1.98 fold as compared plain drug suspension. The optimized formulation 
batch G was found to be stable during six months accelerated stability period. 
Keywords: Acyclovir (ACV), Pellets, Mucoadhesion strength (MS), Ex vivo residence (ES), 
Dissolution 
 
Introduction 
For many decades, conventional dosage forms are used for the 
treatment of acute and chronic diseases which provide no control 
over the release of drug. To maintain the drug concentration within 
the therapeutically effective range, it is often necessary to 
administer the conventional dosage forms several times a day. 
This results in significant fluctuations in drug plasma levels and 
patient incompliance. Sustained release formulation has several 
advantages over conventional dosage formulation as it provides 
improved patient compliance and maintenance of steady state 
plasma drug concentration leading to better disease control and 
reduced intensity of local or systemic side effects.  
Acyclovir or Acyclovir, chemically acycloguanosine, is a guanosine 
analogue antiviral is seen as the start of a new era in antiviral 
therapy, as it is extremely selective and low in cytotoxicity [1]. 
Mechanism of its antiviral activity involves selective conversion into 
acyclo-guanosine monophosphate (acyclo-GMP) by viral thymidine 
kinase, which is far more effective (3000 times) in phosphorylation 
than cellular thymidine kinase, subsequently the monophosphate 
form is further phosphorylated into the active triphosphate form, 
acyclo-guanosine triphosphate (acyclo-GTP), by cellular kinases. 
Acyclo-GTP is a very potent inhibitor of viral DNA polymerase. It 
has approximately 100 times greater affinity for viral than cellular 
polymerase. As a substrate, acyclo-GTP is incorporated into viral 
DNA, resulting in chain termination. The effective treatment of 
genital herpes simplex requires administration of 1000 mg of 
acyclovir in 5 divided doses a day. An alternative dose of 800 mg 
leads to plasma fluctuations; thus an SR dosage form of acyclovir 
is desirable [2, 3].  
The aim of present study is to prolong the residence time of 
dosage form in stomach in order to improve the absorption of drug 
throughout upper gastrointestinal tract and subsequently 
bioavailability by formulating gastroretentive mucoadhesive SR 
pellets. Pellets dosage form was selected as it offers several 
advantages over single unit dosage forms [4-10]. In the 
pharmaceutical industry, pellets can be defined as agglomerates of 
fine powders or granules of bulk drugs and excipients [11]. 
Materials and Methods 
Materials 
Acyclovir was obtained as a gift sample from Cipla Pharamceutical 
Ltd. (India). HPMC K 100M (Methocel® K100M) obtained as gift 
sample from Colorcon Asia Pvt. Ltd. (India), Microcrystalline 
Cellulose (Avicel PH-102) and Sodium carboxy methyl cellulose 
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(Carmellose sodium) from Signet Chemical corporation (India). 
Other chemicals used were of analytical grade. 
Saturation solubility study 
Saturation solubility measurement was performed by standard 
shake flask method (BOEKEL, USA) at 37 °C at 20 rpm for 48 h. 
Solubility was determined in both water and 0.1N HCl (pH 1.2). For 
solubility study, an excess amount of the samples (20mg) were 
dispersed in 10 ml of media. After 48 h of shaking, samples were 
filtered through 0.2 µm membrane filters (PALL life sciences, India) 
and the filtrate was appropriately diluted with the medium used for 
solubility analysis. The measurement was conducted using UV-
Visible Spectrophotometer V-530 at 254 nm (JASCO, Japan) [12]. 
Preparation of gastroretentive  mucoadhesive SR 
pellets 
Several batches have been prepared to achieve desire sustained 
drug release profile. MCC was used as an extrusion aid. 
Compositions for different batches are given in Table 1. 
For pellets preparation all the ingredients were weighed accurately, 
mixed thoroughly and sifted through a 40 mesh sieve. This dry 
powder blend was transferred to Hobart mixer. The required 
amount of purified water (100 ml) was sprayed slowly to the 
powder blend and the system was mixed for 10 min with scraping 
the sides of the bowl and the blade at regular intervals. Wet mass 
obtained was fed into inlet of single screw extruder with 1 mm 
diameter (S.B. Panchal & company, India). The wet mass was 
extruded at speed of 45 rpm. The wet extrudate was spheronized 
for 10 min at 1000 rpm on a 12 cm diameter crosshatched plate of 
a spheronizer (Unisphere- lab spheronizer, S.B. Panchal & 
company, India). The pellets were dried in a hot air oven (Metalab, 
India) at 60 ○C for 6 h to achieve constant weight. Screening was 
carried out to separate oversized and undersized pellets. The 
pellets which were retained on 18 mesh sieve were collected. 
Sieving was carried out to get uniform sized pellets.  
Coating of drug loaded pellets with mucoadhesive 
polymer 
Pellets retained on 18 mesh sieve were used for coating purpose. 
Approximately 100g of ACV pellets subjected for coating in a 500 
gm capacity lab scale coating pan. 1% solution of sodium carboxy 
methyl cellulose was prepared and sprayed over the pellet surface 
in tablet coater (Tablet pan coater MSW-709, Macro scientific 
works, India). Processing parameters involved, pan speed 32 rpm, 
spray rate 450mg/min, distance of gun from pellet bed was 12 cm 
and air pressure was kept at 1.5 kg/cm2 .The polymer coating was 
done at level of 1% w/w and 3% w/w weight gain.  
Characterization of drug loaded pellets 
Particle size distribution  
 Particle size distribution was determined using mechanical sieve 
shaker. 10 g of the pellets were   sifted through a series of sieves 
(12, 16, 18 and 24 mesh). The machine was operated for 5 
minutes and % retained on respective sieve was calculated. The 
average particle size was determined. 
Density and flow property 
All formulation batches were also evaluated for their physical 
properties like bulk density, tap density (Veego, India), friability 
(Friability apparatus, Veego, India), flow property in terms of angle 
of repose [13]. All these parameters affect the processing of final 
formulation. 
 
Loss on drying (LOD) 
Loss on drying (LOD) was determined by gravimetric technique. A 
weighed quantity of pellets (10 g) were kept for drying in hot air 
oven at 60 ○C and loss in weight was calculated at regular time 
interval till constant weight. 
Image analysis  
The sphericity of the pellets was determined using derived pellet 
parameters measured by an image analysis system (optical 
microscope, DMWBI-223ASC motic digital microscope). A random 
sample of 150–200 pellets from each batch of product was 
examined and a roundness factor was calculated as follows: 
 
Roundness factor = P2m/4piA 
Where, Pm is the perimeter length and A is the projected area. A 
perfectly round pellet would have a value of 1.0 irrespective of size 
and the value would tend towards 10.0 for pellets that were 
progressively non-spherical [14]. 
Swelling property  
Swelling property was determined for each formulation batch. A 
weighed amount of pellets (10 g) were placed in a 100 ml 
measuring cylinder containing pH 1.2 media. Initial volume (Vo) 
was noted and change in physical volume was observed (Vt) at 
regular interval for 6 h [15]. The degree of swelling was calculated 
using following formula: 
 
Degree of Swelling = Vt -Vo/Vo 
Measurement of mucoadhesion strength 
Mucoadhesive strength of the SR pellets was measured using 
reported modified physical balance method [16]. To make 
measurement easier, a disc of pellets were prepared using 10 mm 
standard flat surface punches on a single punch tablet machine 
(Cadmach, Ahmedabad, India)). A modified double beam physical 
balance was used in which the right pan has been replaced by a 
glass slide with copper wire and to make the right side weight 
equal with left side pan some additional weight was placed 
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(reference). The porcine gastric mucus membrane collected from 
local slaughter house was used as model membrane and a pH 1.2 
solution was used as the moistening fluid. The porcine stomach 
mucosa was maintained in Tyrode solution at 37 ○C till further use. 
From the mucoadhesive strength, the force of adhesion was 
calculated using the following formula: 
   
 Force of adhesion (N) =  Bioadhesive strength × 9.81 
                                                          100  
 
Bond strength (N/m2) =     Force of adhesion (N) 
                                      Surface area of tablet (m2) 
Ex vivo residence time 
The mucoadhesion property of SR pellets was determined 
according to earlier reported method [17]. A 5 cm long piece of 
freshly cut sheep intestine was obtained from a local 
slaughterhouse, cleaned by washing with isotonic saline solution 
and used within 1 hr of slaughter. An accurately weighed amount of 
pellet was placed on the mucosal surface, which was attached to a 
polyethylene plate that was fixed at an angle of 40° relative to the 
horizontal plane. pH 1.2 buffer maintained at 37±1°C was passed 
at a rate of 5 ml/min over the tissue. The time required for 
detaching all the pellets from mucosal surface of the sheep 
intestine was recorded by visual inspection. The experiments were 
performed in triplicate. 
Determination of drug content 
A weighed amount of SR pellets (10 mg) were ground to powder 
and suspended in 100 ml of purified water, shaken for 10 min and 
filtered. Filtrate was suitably diluted with purified water and 
analyzed using UV spectrophotometer V-530 a t 254 nm (JASCO, 
Japan) [18]. 
In vitro drug release 
Dissolution test was carried out using six station USP XXIII (TDT-
06T Electrolab, Mumbai, India) dissolution apparatus. Pellets 
equivalent to 50 mg of drug filled in capsule and subjected for 
dissolution. The test was performed at a paddle speed of 50 rpm in 
900 ml of 0.1N HCl (pH 1.2) buffer for 12 h, temperature 
maintained at 37 ± 0.5 ○C. An aliquot of 5 ml was withdrawn and 
same amount of fresh medium was replaced to maintain the sink 
condition. The absorbance was measured after appropriate dilution 
at 254 nm using UV spectrophotometer. Drug concentration was 
determined using standard plot of absorbance versus drug 
concentration. Dissolution was performed in triplicate. 
Mathematical model fitting of in vitro drug release 
To analyze the in vitro release mechanism, data obtained from 
dissolution fitted to different kinetic models like zero order, first 
order, Higuchi and Korsmeyer Peppas [14, 19].  
In vivo study 
Animal experimental procedure  
All experimental procedures were reviewed and approved by the 
institutional animal ethics committee of University department of 
chemical technology (Aurangabad, India). Wister rats were fasted 
for 24 h before the experiment and food was reoffered after 4h 
post-dosing. The rats were divided into two groups of five animals 
each. Each group was orally administered optimized batch G and 
plain Acyclovir suspension, equivalent dose of 40 mg/kg/ml of 
saline body weight as acyclovir. Blood samples were collected from 
retro-orbital venous plexus of rats at predetermined time intervals (t 
= 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 h). Blood sample was centrifuged for 
10 min to separate plasma at 4000 rpm (research centrifuge TC 
4100 D, Remi, India) and stored at −20 ○C till further analysis. 
Extraction procedure and analytical conditions for 
Acyclovir 
100 µl rat plasma samples was taken in centrifuge tube and mixed 
well. Then 100 µl 12 .5% trichloroacetic acid solution was added 
and vortex for 1 minute. The mixture was centrifuged at 9000 rpm 
for 10 min, and 150 µl of the resultant supernatant was transferred 
to a clean centrifuging tube and neutralized with 50 µl 1M NaOH. 
To remove substances that interfere with the objective peaks in the 
chromatograms, 500 µl n-hexane was then added. The mixture 
was vortex for 1 minute and centrifuged at 9000 rpm for 10 min. 
After aspirating the organic layer, 50 µl of the resultant aqueous 
layer was injected onto the HPLC system (19). The liquid 
chromatograph (Jasco LC-10AS, Kyoto, Japan) was equipped with 
column (150mm×4.6mm, 5µm) attached to a C18 guard column 
(7.5mm×4.6mm, 5µm) at 40 ○C. The mobile phase consisted of 
methanol and water in ratio of (1:99) adjusted to pH 2.0 with 
perchloric acid. Flow rate was kept 1 ml/min, and detection was 
carried out using a UV detector (Shimadzu SPD-10A) at 280 nm. 
The method was linear between 5 and 25 µg/ml. 
Stability study 
Optimized formulation (batch G) was subjected for stability study. 
Stability study was carried out as per ICH guidelines [21]. The 
prepared pellets were stored in a humidity chamber with relative 
humidity of 75 ± 5 % and temperature of 40 ± 2 °C or at room 
temperature for 6 months. Samples were withdrawn at time 0, 1, 3 
and 6 months. Samples were evaluated for their physical 
characteristics, dissolution behavior and drug content.  
Fourier transform infrared spectroscopy 
Drug polymer interaction was studied by FTIR spectroscopy 
(OPUS, Bruker, Germany). The spectra were recorded for pure 
drug and drug loaded pellets using FTIR. Samples were prepared 
as potassium bromide (KBr) disks by means of a hydrostatic press. 
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The scanning range was 550 to 4000 cm–1 and the resolution was 
4 cm–1. 
Differential scanning calorimetry 
DSC analysis was performed using PERKINELMER DSC Pyris -6 
(USA) on 2 to 8 mg sample. Sample was heated in an aluminum 
pan at a rate of 10 °C / min within a 30 to 300°C temperature range 
under a nitrogen flow of 20 ml/min. An empty sealed pan was used 
as a reference. 
Results and Discussion 
Saturation solubility    
Solubility of acyclovir was found to be 2.4 mg/ml and 0.66 mg/ml in 
water and pH 1.2 buffer respectively. Drug content analysis of all 
the formulation batches showed high drug content uniformity with 
98.5-100.5% ACV. 
Particle shape and size distribution   
 Image analysis indicated that pellets from C, F and G batches 
produces spherical particles with roundness factor 0.999, 1 and 1 
respectively. Batches A and E had rod shaped irregular pellets 
whereas batches B, D and H produced variable sized pellets 
Figure 1. Roundness factor for all the batches are provided in table 
2. Sieve analysis showed that 96-99% of pellets fall under particle 
size of 1000 µm and showed uniform particle size distribution 
(Table 3). 
 
Table 2. Pellets shape defining roundness factor 
Batch No. Roundness factor 
A 1.514 
B 1.000 
C 0.999 
D 1.197 
E 1.411 
F 1.000 
G 1.000 
H 0.999 
 
Density  
 Bulk density and tap density are the measures for bulkiness of a 
formulation. Result showed that there were no significant 
differences observed in bulk density and tap density due to 
spherical shape of pellets.Values obtained from angle of repose 
indicated that prepared pellets had good flow. Pellets friability was 
found to be within pharmacopoeial acceptable range and there was 
no significant loss in weight observed on drying. Data for physical 
parameters evaluation given in table  4. 
Degree of swelling  
From A to D, maximum swelling was found at 4 h; from these, D 
was found to show high swelling of 500.85° at 4 h. Degree of 
swelling for E and H was also found to be nearly same as D 
whereas maximum swelling property was observed with F and G 
Batch at 3 h. The comparison of degree of swelling of all 
formulations is shown in Figure 2. It was observed that as the 
HPMC K 100M concentration in formulations increases, swelling 
property gradually increases Figure 2. 
Mucoadhesion strength and Ex vivo residence time 
All the formulations batches were evaluated for these parameters 
in triplicate (Table 5). Gradual increase in mucoadhesion strength 
(MS) and ex vivo residence (ER) time was observed from batch A 
to H. This adhesive property will increase with the degree of 
hydration until a point where over hydration leads to a sudden 
decline in MS, which might be due to the disentanglement at the 
polymer/tissue interface. The degree of swelling was increased 
with the increase in the concentration of Na CMC and HPMC K 
100M . Batch A was found to have low MS and ER of 3.33 g and 
2.43 h, respectively. MS and ER for different batches are given in 
Table V. For uniform and prolonged release of drug, an appropriate 
degree of swelling and mucoadhesion is required. The maximum 
MS and ER was found for batches G and H. 
Table 5. Results of mucoadhesion strength and ex vivo residence 
time of all pellets formulations  
Batch no. MS  (g)        ER (h) 
A 3.33±0.031 2.43±0.231 
B 4.15±0.022 3.74±0.312 
C 6.42±0.021 5.5±0.271 
D 8.25±0.023 7.56±0.312 
E 10.27±0.020 6.85±0.501 
F 13.5±0.023 8.34±0.541 
G 16.34±0.031 7.01±0.461 
H 18.45±0.023 9.56±0.801 
 
In vitro drug release 
The comparison of cumulative drug release of all formulations is 
shown in Figure 3 and Figure 4 as well as in table 6. Formulations 
A, B and C were found to release approximate 40% of drug within 
first hour whereas formulation D released 25% drug in the same 
time but these formulations were able to sustain the release upto 8 
h only. An ideal sustained release system should be able to 
release the drug immediately to attain the therapeutic level at a 
faster rate and maintain this drug level for a prolonged period of 
time. Formulation batches from E to H showed 25% drug release 
within first hour and able to sustain  the drug release for 12 h due 
to the presence of higher amount  of  HPMC K 100M and Na CMC 
coating level.  The drug release profile of formulations F and G was 
found to be same. Formulation G was taken as an optimized  batch  
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since  it  had  higher  MS,  ER  and  desired  drug  release  profile. 
The optimized formulation G showed good drug content uniformity 
and insignificant change in dissolution profile during the stability 
period. 
The n and R2   values for zero order, first-order, Higuchi and 
Peppas were represented in Table 7.The results indicated that the 
best linearity was found in Higuchi’s equation (r2 = 0.9948) 
indicating the release of drug from matrix as a square root of time 
dependent process based on Fickian diffusion. The value of the 
release exponent (n) in acyclovir sustained release obtained as 
0.2135 (was very low) which is beyond the limit value of 0.5-1 of 
Korsmeyer model so-called power law. So as per n value drug 
release mechanism was found to be very complex involving 
swelling, diffusion and erosion. Generally water penetration, 
polymer swelling, drug dissolution, drug diffusion and matrix 
diffusion from dosage form are controlled by rate of hydration of 
HPMC, which forms a gel barrier [16].  
Pharmacokinetic study 
The mean plasma concentration of ACV-time profiles after oral 
administration of acyclovir loaded mucoadhesive pellets and 
acyclovir suspension are illustrated in Figure 5. After administration 
of the drug suspensions, plasma drug concentration achieved at its 
maximum level within 1 hand then decreased rapidly whereas the 
profiles for drug-loaded mucoadhesive pellets (batch G) was found 
to be constant. A peak plasma concentration was observed in 2 h, 
which could be kept in a relatively steady state for 8 h and plasma 
concentration falls below detection level in 12 h. The 
pharmacokinetic parameters are listed in Table 8. The Cmax 
values for acyclovir loaded gastroretentive mucoadhesive pellets 
and acyclovir suspension were 598 ng/ml and 674 ng/ml, 
respectively. The oral bioavailability of acyclovir was greatly 
improved as the relative bioavailability values was 198% for 
acyclovir loaded mucoadhesive gastroretentive pellets compared 
with that of acyclovir suspension, which was attributed to the 
prolonged residence of microspheres in gastrointestinal tract and 
induced close contact of drug at its absorption site to enhance the 
absorption  
Fourier transform infrared spectroscopy 
Acyclovir has characteristic band in IR,  NH stretching: a single 
band at 3552 cm-1, NH stretching: a forked band at 3500 cm-1 , OH 
stretching: a broad peak at 3315 cm-1 , -CH stretching (aromatic) a 
single band at 3184 cm-1,  –CH  stretching (aliphatic) a single band 
at 2712 cm-1 (This was normally observed at 2933 cm-1, however 
due to the intramolecular hydrogen bond between the –NH2 and –
OH, it was shifted to 2712 cm-1), HC (=O)NH2 stretching  (Cyclic 
amide): a single peak at1716 cm-1.The FTIR spectral analysis 
showed that there was no appearance or disappearance of any 
characteristic peaks of acyclovir in the optimized formulation, 
confirms the absence of chemical interaction between drug and 
polymers Figure 6.  
Differential scanning calorimetry 
DSC thermograms of ACV and optimized SR pellets formulation 
containing ACV and polymer were shown in Figure 7. A sharp 
endothermic peak (Tm) at 252.22 °C, with the enthalpy of fusion 
being 455.399 J/g, corresponding to melting point of ACV was 
obtained. DSC thermogram of optimized formulation did not show 
any change in ACV sharp endothermic peak indicated absence of 
chemical interaction between drug and polymer and suitability of 
formulation. 
 
Table 1. Formulation compositions of different SR pellets batches 
Sr. no. Ingredients (g)/Batch Code A B C D D E F H 
1 Acyclovir 20 20 20 20 20 20 20 20 
2 HPMC K 100 M 10 10 20 20 30 30 40 40 
3 Microcrystalline cellulose 70 70 60 60 50 50 40 40 
4 Sodium CMC 1% 3% 1% 3% 1% 3% 1% 3% 
5 Magnesium stearate 1% 1% 1% 1% 1% 1% 1% 1% 
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Table 3. Particle size distribution (n=3, ±SD) 
Batch No. % of pellets retained on screen mesh* 
1700 µm 1180 µm 1000 µm 710 µm 
A 0.0000±0.000 0.0666±0.066 99.1333±0.570 0.8000±0.600 
B 0.2000±0.115 1.8000±1.102 97.2666±1.636 0.4000±1.302 
C 0.0666±0.066 1.3333±0.941 97.8666±1.334 0.7333±0.467 
D 0.1333±0.066 2.0000±1.502 96.8666±2.436 1.0000±1.001 
E 0.3333±0.333 1.2666±1.074 96.7333±2.387 1.6666±1.472 
F 0.1333±0.133 0.7333±0.732 98.333±1.169 0.8000±0.305 
G 0.6667±0.176 0.9333±0.353 98.2000±0.503 0.1333±0.133 
H 0.6000±0.305 0.4666±0.176 98.4666±0.266 0.4666±0.134 
 
Table 4. Physical characterizations of SR pellets (n=3, ±SD) 
Batch Bulk density 
(g/cc) 
Tapped density 
(g/cc) 
Angle of 
repose (θ) 
Friability (%) Loss on 
drying (%) 
A 0.7702 ± 0.028 0.7896 ± 0.002 18 0.2 0.2 
B 0.7563 ± 0.032 0.8700 ± 0.013 22 0.4 0.0 
C 0.7780 ± 0.026 0.8183 ± 0.014 25 0.2 0.1 
D 0.7408 ± 0.015 0.8256 ± 0.028 24 0.2 0.0 
E 0.7473 ± 0.009 0.8026 ± 0.000 19 0.2 0.0 
F 0.7400 ± 0.002 0.7913 ± 0.003 18 0.4 0.3 
G 0.8220 ± 0.003 0.8430 ± 0.023 20 0.4 0.0 
H 0.7306 ± 0.009 0.8326 ± 0.014 18 0.0 0.0 
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Table 6. In vitro drug release of all acyclovir SR pellets batches (n=3, ±SD) 
 
Time (h) Percent Cumulative Release 
 Batch A Batch B Batch C Batch D Batch E Batch F  Batch G Batch H 
0 
0 0 0 0 0 0 0 0 
1 
40±2.1 35±2.27 34±3.1 30±2.2 28.01±2 29.73±2.1 27.78±3 18.45±2.2 
2 
50±4.3 40.62±3.4 45.64±3.3 32±3.3 40.3±4.3 41.43±3.0 40.18±3.5 32.58±3.3 
3 
60±4.1 51.16±4.5 56.16±3.5 45.5±5 47.27±4 51.09±4.3 46.54±3.5 42.58±3.8 
4 
65.6±3. 62.95±3.3 66.38±4.1 60.32±3 53.26±3 60.28±3.5 58.12±4.0 50.12±3.4 
5 
75.4±4 75.98±4.4 74.41±3.5 75.14±4 59.45±4 69.35±4.2 62.12±3.4 57.12±4.3 
6 
85.5±3.5 86.21±3.1 85.96±3.6 84.96±3 65.86±3 76.89±3.4 75.12±3.5 63.18±3.5 
7 
95±3.4 93.45±5 95.48±4.5 94.15±4 72.78±3 83.43±5 79.25±4.3 66.96±3.2 
8 
99±3.2 100.21±4 101.05±3 99.25±3 79.07±2 86.68±4.1 82.18±3.3 70.78±3 
9 
- - - - 85.23±4 89.77±3.2 85.36±2.1 75.65±4 
10 
- - - - 90.75±4 93.22±4.8 88.89±3.9 78.69±3.3 
11 
- - - - 95.79±3 96.17±3 95.12±4.4 89.24±3.3 
12 
- - - - 99.84±4 98.25±2 99.45±3.2 94.17±4 
 
Table 7. Kinetics of in vitro drug release of all formulations 
Batch No. Zero order 
R2 
First order 
R2 
Higuchi 
R2 
Korsmayer- Peppas 
R2 n 
A 0.9926 0.9037 0.9251 0.9892 0.4216 
B 0.9158 0.9392 0.9839 0.9901 0.2984 
C 0.9518 0.9025 0.9930 0.9838 0.2778 
D 0.9829 0.8274 0.9422 0.9538 0.4360 
E 0.9428 0.6980 0.9935 0.9846 0.2141 
F 0.8901 0.9600 0.9926 0.9429 0.2043 
G 0.9153 0.8022 0.9948 0.9565 0.2134 
H 0.9430 0.9130 0.9904 0.9313 0.2512 
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Table 8. In-vivo pharmacokinetic parameters and relative bioavailability of formulation G SR pellets and ACV suspension. 
Formulation Tmax (h) Cmax (ng/ml) AUC 0-12h (ng.h/ml) Fr (%) 
ACV suspension 1.10± 0.25 598±0.54 3231.23±214.54 100.00 
ACV SR pellets (G) 1.15±0.34 674±0.87 6397.38±324.65 198.00 
n = 6; Data are means ±SD 
 
Figure 1. Image analysis of SR pellets batches 
 
Figure 2. Degree of swelling vs time profile of all SR pellets formulation  
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Figure 3. In vitro drug release of acyclovir SR pellets  
 
Fig 4. In vitro drug  release  of  acyclovir  SR  pellets. 
 
Figure 5. Plasma concentration time profiles of ACV suspension and formulation G SR pellets 
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Figure 6. FTIR spectra of (A) ACV, (B) microcrystalline cellulose, (C) Sodium CMC, (D)HPMC K 100M and (E) Optimized formulation 
 
 
Figure.7 DSC thermogram of (A) ACV and (B) Optimized formulation 
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Conclusions 
Sustained release pellets of acyclovir was developed using HPMC 
K 100M matrix forming agent by the extrusion spheronization 
method showed good results in terms of mucoadhesion, ex vivo  
residence time, sustained drug release. Kinetic models revealed 
that it follows Higuchi’s model and drug release by complex 
mechanisms of swelling, diffusion and erosion. Relative 
bioavailability of SR pellets also gets increased by two fold. 
Optimized formulation was found to  be stable for the period of 
stability study. In conclusion, we suggest that SR system for 
acyclovir administration can be alternative way to conventional 
system as it offers several advantages such as increased 
bioavailability, sustained drug release and improved patient 
compliance. 
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